Specialized Treatments for Patients with Hematologic Conditions

The Stem Cell Transplant Program at UH Seidman Cancer Center has an internationally recognized legacy of innovative adult and pediatric transplantation. Our experts in stem cell transplant, graft-versus-host disease, leukemia, novel cell therapy and other hematologic malignancies and marrow disorders are leaders in innovation and specialized treatments. We treat pediatric and adult patients up to age 75 with a full range of hematologic conditions, including:

• Acute and chronic leukemia
• Myelodysplastic syndrome
• Metabolic storage disorders
• Multiple myeloma
• Hodgkin disease and non-Hodgkin lymphoma
• Bone marrow failure states and aplastic anemia
• Sickle cell anemia
• Amyloidosis

A strong emphasis on translational research leads to the development of new drugs and cell therapy approaches for hematologic malignancies, with and without classic stem cell transplant. Our physicians are pioneers in cancer research related to:

• Autologous transplantation for patients with lymphoma
• Umbilical cord blood transplantation for patients without a compatible marrow donor
• Mesenchymal stem cells to hasten engraftment
• Hematopoietic growth factors in transplantation

The Stem Cell Transplant Program offers:

• Coordinated communication with the referring physicians
• Consultations to outline treatment options
  Access to advanced scientific technologies and innovations including more than 300 clinical trials
• A 26-bed inpatient unit dedicated to stem cell transplantation and treatment of patients with hematologic malignancies
• The Clinical Research Suite allowing for the safe administration of new agents in a highly monitored setting
• Cellular Therapy Integrated Service, a unique clean room facility providing cells for both standard-of-care treatments and investigational studies
• The Center for Cancer Drug Development, which leads and coordinates all Phase l clinical trials in novel cancer agents in research